Last reviewed · How we verify

Hydrea® (hydroxyurea ) — Competitive Intelligence Brief

Hydrea® (hydroxyurea ) (Hydrea® (hydroxyurea )) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite; ribonucleotide reductase inhibitor. Area: Oncology; Hematology.

marketed Antimetabolite; ribonucleotide reductase inhibitor Ribonucleotide reductase Oncology; Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Hydrea® (hydroxyurea ) (Hydrea® (hydroxyurea )) — Assistance Publique - Hôpitaux de Paris. Hydroxyurea inhibits ribonucleotide reductase, reducing deoxyribonucleotide synthesis and slowing DNA replication in rapidly dividing cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Hydrea® (hydroxyurea ) TARGET Hydrea® (hydroxyurea ) Assistance Publique - Hôpitaux de Paris marketed Antimetabolite; ribonucleotide reductase inhibitor Ribonucleotide reductase
Gemzar Gemcitabine Hydrochloride Accord Hlthcare marketed Nucleoside metabolic inhibitor Ribonucleotide reductase; DNA incorporation 1996-01-01
HYDROXYUREA HYDROXYUREA marketed Antimetabolite [EPC] Ribonucleotide reductase 1967-01-01
Gemcitabine (GEM) Gemcitabine (GEM) Sun Yat-sen University marketed Nucleoside analog; antimetabolite Ribonucleotide reductase; DNA polymerase
Fludarabine (FLU) Fludarabine (FLU) Nanfang Hospital, Southern Medical University marketed Purine nucleoside analog Ribonucleotide reductase, DNA polymerase
Platinum + Gemcitabine Platinum + Gemcitabine Fondazione Policlinico Universitario Agostino Gemelli IRCCS marketed Chemotherapy combination (platinum agent + nucleoside analog) DNA (platinum crosslinking); ribonucleotide reductase and DNA polymerase (gemcitabine)
Gemcitabine-Cisplatin chemotherapy Gemcitabine-Cisplatin chemotherapy Simcere Pharmaceutical Co., Ltd marketed Chemotherapy combination (nucleoside analog + platinum agent) DNA (multiple targets including ribonucleotide reductase inhibition and DNA cross-linking)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Antimetabolite; ribonucleotide reductase inhibitor class)

  1. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
  2. Bionoxx Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hydrea® (hydroxyurea ) — Competitive Intelligence Brief. https://druglandscape.com/ci/hydrea-hydroxyurea. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: